Zenith Drugs (NSE:ZENITHDRUG) Short-Term Debt: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ZENITHDRUG Zenith Drugs Ltd NSE:ZENITHDRUG
38 GF Score
Price ₹44.65
! 7 Warning Signs
View Full Analysis

What is Zenith Drugs Short-Term Debt?

Zenith Drugs NSE:ZENITHDRUG +2.88% 38 Short-Term Debt is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:ZENITHDRUG with a GF Score™ of 38/100. The stock has 7 warning signs investors should review.

Zenith Drugs's Short-Term Debt for the quarter that ended in Mar. 2026 was ₹0 Mil.

Zenith Drugs's quarterly Short-Term Debt declined from Mar. 2025 (₹358 Mil) to Sep. 2025 (₹0 Mil) but then stayed the same from Sep. 2025 (₹0 Mil) to Mar. 2026 (₹0 Mil).

Zenith Drugs's annual Short-Term Debt increased from Mar. 2024 (₹161 Mil) to Mar. 2025 (₹358 Mil) but then declined from Mar. 2025 (₹358 Mil) to Mar. 2026 (₹0 Mil).

Zenith Drugs Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Zenith Drugs Short-Term Debt Related Terms

Zenith Drugs Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Zenith Drugs's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenith Drugs Short-Term Debt Chart

Zenith Drugs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial 92.38 175.87 160.80 357.73 0.00

Zenith Drugs Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 160.80 0.00 357.73 0.00 0.00
NSE:ZENITHDRUG
38GF Score
Zenith Drugs Ltd NSE:ZENITHDRUG
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹0 Mil mean?
Zenith Drugs (NSE:ZENITHDRUG) has a Short-Term Debt of ₹0 Mil as of Mar. 2026.
Is Zenith Drugs' Short-Term Debt too high?
Zenith Drugs' current Short-Term Debt is ₹0 Mil. Overall, Zenith Drugs has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Zenith Drugs' Short-Term Debt compare to ZTS?
Zenith Drugs' Short-Term Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Zenith Drugs's current Short-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenith Drugs stock overvalued right now?
Zenith Drugs (NSE:ZENITHDRUG) has a current Short-Term Debt of ₹0 Mil. The current Short-Term Debt is ₹0 Mil. Zenith Drugs' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Zenith Drugs (NSE:ZENITHDRUG), the current Short-Term Debt is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenith Drugs Business Description

Address K. No. 72/5, Village Muradpura, Depalpur, Indore, MP, IND, 453001
Zenith Drugs Ltd is a pharmaceutical manufacturing and trading company. It offers a wide range of formulations in various forms such as ORS Powder, Liquid Orals, Ointments, Liquid Externals, Creams, Gels, Capsules, and Tablets. It is also into Generic Medicines.
38GF Score

Get the complete analysis for NSE:ZENITHDRUG

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹44.65
Price